Lakewood-Amedex Biotherapeutics holds annual shareholder meeting
LABT•Shareholders approved raising authorized common shares to 100 million from 12.5 million and authorized the board to execute reverse stock splits up to a cumulative 1-for-20 ratio.
1. Shareholder approvals
At its Sept. 22 annual meeting, Lakewood-Amedex Biotherapeutics shareholders approved an amendment increasing authorized common shares to 100 million from 12.5 million and authorized the board to execute one or more reverse stock splits with a cumulative ratio of up to 1-for-20. They also adopted an amendment increasing the 2020 equity incentive plan share pool to 400,000 and ratified CBIZ CPAs as the independent registered public accounting firm.
